glucagon-like-peptide-1-(7-36) has been researched along with Body-Weight* in 3 studies
1 trial(s) available for glucagon-like-peptide-1-(7-36) and Body-Weight
Article | Year |
---|---|
Effect of 24-h severe energy restriction on appetite regulation and ad libitum energy intake in lean men and women.
Intermittent severe energy restriction (SER) can induce substantial weight loss, but the appetite regulatory responses to SER are unknown and may dictate long-term dietary adherence.. We determined the effect of 24-h SER on appetite regulation, metabolism, and energy intake.. Eighteen lean men and women completed two 3-d trials in randomized, counterbalanced order. On day 1 subjects consumed standardized diets containing 100% (mean ± SD: 9.3 ± 1.3 MJ; energy balance) or 25% [2.3 ± 0.3 MJ; energy restriction (ER)] of energy requirements. On day 2, a standardized breakfast was consumed, with plasma concentrations of acylated ghrelin, glucagon-like peptide 1, insulin, glucose, and nonesterified fatty acids determined for 4 h. Ad libitum energy intake was assessed at lunch and dinner with subjective appetite and resting metabolism assessed throughout. On day 3, ad libitum energy intake was assessed at breakfast and by weighed food records.. Energy intake was 7% greater on day 2 (P < 0.05) during ER but not significantly different on day 3 (P = 0.557). Subjective appetite was greater during ER on the morning of day 2 (P < 0.05) but was not significantly different thereafter (P > 0.145). During ER, postprandial concentrations of acylated ghrelin were lower (P < 0.05), whereas glucose (P < 0.05) and nonesterified fatty acids (P < 0.0001) were higher. Postprandial glucagon-like peptide 1. In lean young adults, 24-h SER transiently elevated subjective appetite and marginally increased energy intake, but hormonal appetite markers did not respond in a manner indicative of hyperphagia. These results suggest that intermittent SER might be useful to attenuate energy intake and control body weight in this population. This trial was registered at www.clinicaltrials.gov.uk as NCT02696772. Topics: Acylation; Adult; Appetite; Appetite Regulation; Blood Glucose; Body Mass Index; Body Weight; Breakfast; Caloric Restriction; Cross-Over Studies; Energy Intake; Energy Metabolism; Fatty Acids, Nonesterified; Female; Ghrelin; Glucagon-Like Peptide 1; Humans; Insulin; Male; Meals; Nutritional Requirements; Peptide Fragments; Postprandial Period; Young Adult | 2016 |
2 other study(ies) available for glucagon-like-peptide-1-(7-36) and Body-Weight
Article | Year |
---|---|
Comparison of Beinaglutide Versus Metformin for Weight Loss in Overweight and Obese Non-diabetic Patients.
We compared the efficacy and safety of beinaglutide, a glucagon-like peptide-1 (GLP-1) analogue with metformin in lowering the bodyweight of patients who were overweight/obese and non-diabetic.. Seventy-eight non-diabetic patients were randomly selected and beinaglutide or metformin was administered for 12 weeks. The primary endpoints were changes in body weight and the proportions of patients who lost≥5 and≥10% of their baseline body weights.. A total of 64 patients completed the study; patients in the beinaglutide group exhibited more bodyweight loss than those in the metformin group [(9.5±0.8%; 9.1±0.9 kg) and (5.1±0.9%; 4.5±0.8 kg), respectively, corresponding to a difference of approximately 4.5 kg (95% confidence interval, 2.2-6.9 kg;. Beinaglutide is more efficient than metformin at reducing weight and fat mass in patients who are overweight/obese and non-diabetic. Beinaglutide may be a useful therapeutic option for overweight/obesity control in the Chinese population. Topics: Body Weight; Diabetes Mellitus, Type 2; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Metformin; Obesity; Overweight; Peptide Fragments; Weight Loss | 2022 |
Evaluation of glycated glucagon-like peptide-1(7-36)amide in intestinal tissue of normal and diabetic animal models.
Glucagon-like peptide-1(7-36)amide (tGLP-1) is an important insulin-releasing hormone of the enteroinsular axis which is secreted by endocrine L-cells of the small intestine following nutrient ingestion. The present study has evaluated tGLP-1 in the intestines of normal and diabetic animal models and estimated the proportion present in glycated form. Total immunoreactive tGLP-1 levels in the intestines of hyperglycaemic hydrocortisone-treated rats, streptozotocin-treated mice and ob/ob mice were similar to age-matched controls. Affinity chromatographic separation of glycated and non-glycated proteins in intestinal extracts followed by radioimmunoassay using a fully cross-reacting anti-serum demonstrated the presence of glycated tGLP-1 within the intestinal extracts of all control animals (approximately 19% of total tGLP-1 content). Chemically induced and spontaneous animal models of diabetes were found to possess significantly greater levels of glycated tGLP-1 than controls, corresponding to between 24--71% of the total content. These observations suggest that glycated tGLP-1 may be of physiological significance given that such N-terminal modification confers resistance to DPP IV inactivation and degradation, extending the very short half-life (<3 min) and bioactivity of the native peptide. Topics: Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Disease Models, Animal; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptides; Glycosylation; Hydrocortisone; Intestine, Small; Mice; Mice, Obese; Organ Size; Peptide Fragments; Rats | 2002 |